奥希替尼靶向治疗晚期非小细胞肺癌的疗效及对血清肿瘤标志物的影响  

Efficacy of osimertinib targeted therapy for advanced non-small cell lung cancer and its impact on serum tumor markers

作　　者：周群 罗琴 汪雨珠[1] ZHOU Qun;LUO Qin;WANG Yuzhu(Department of Respiratory and Critical Care Medicine,Ji’an Central People’s Hospital,Ji’an 343000,Jiangxi,China)

机构地区：[1]吉安市中心人民医院呼吸与危重症医学科,江西吉安3430000

出　　处：《癌症进展》2024年第11期1227-1229,1233,共4页Oncology Progress

基　　金：江西省卫生健康委科技计划项目(202140982)。

摘　　要：目的 探讨奥希替尼靶向治疗晚期非小细胞肺癌(NSCLC)的疗效及对血清肿瘤标志物的影响。方法 采用抽签法将79例NSCLC患者分为对照组(n=40)和观察组(n=39),对照组患者给予培美曲塞+顺铂化疗,观察组患者在此基础上接受奥希替尼靶向治疗。比较两组患者的临床疗效、血清肿瘤标志物水平及不良反应发生情况。结果 观察组患者治疗总有效率为76.92%,高于对照组患者的55.00%,差异有统计学意义(P﹤0.05)。治疗后,观察组患者癌胚抗原(CEA)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)、糖类抗原125(CA125)水平均低于对照组,差异均有统计学意义(P﹤0.05)。观察组患者皮疹、白细胞减少、腹泻、肝功能损伤发生率均低于对照组,差异均有统计学意义(P﹤0.05)。结论 奥希替尼靶向治疗联合化疗治疗晚期NSCLC患者的效果较好,可降低血清肿瘤标志物水平和不良反应发生率。Objective To observe the efficacy of osimertinib targeted therapy for advanced non-small cell lung cancer(NSCLC) and its impact on serum tumor markers.Method A total of 79 NSCLC patients were divided into control group(n=40) and observation group(n=39) by drawing lots.The control group received pemetrexed+cisplatin chemotherapy,while the observation group received osimertinib targeted therapy on the basis of the control group.The clinical efficacy,serum tumor marker levels,and adverse reactions were compared between two groups.Result The total effective rate of the observation group was 76.92%,which was higher than 55.00% of the control group,the difference was statistically significant(P<0.05).After treatment,the levels of carcinoembryonic antigen(CEA),cyto-keratin 19 fragment antigen 21-1(CYFRA21-1),carbohydrate antigen 125(CA125) in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The incidence of rash,leukopenia,diarrhea,and liver function damage in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).Conclusion Osimertinib targeted treatment combined with chemotherapy in advanced NSCLC has a good effect,which can reduce serum tumor marker levels and incidence of adverse reactions.

关 键 词：非小细胞肺癌 奥希替尼 靶向治疗 肿瘤标志物 

分 类 号：R734734.2[医药卫生—肿瘤]